Featured content in this Issue: *** Already this month we have seen two financing or dealmaking events among psychedelics companies that have rallied investors and company execs alike. In the first week of May, a weary Reunion Neuroscience surprised many by announcing a $103M Series A round to progress its 4-HO-DiPT prodrug candidate through a suite of Phase 2 studies (see Reunion…


Previous articleDepth Psychology, Archetypal Energies, and How Psychedelics Reveal the Soul
Next articleBreaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?